BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Leiser SC, Iglesias-Bregna D, Westrich L, Pehrson AL, Sanchez C. Differentiated effects of the multimodal antidepressant vortioxetine on sleep architecture: Part 2, pharmacological interactions in rodents suggest a role of serotonin-3 receptor antagonism. J Psychopharmacol 2015;29:1092-105. [PMID: 26174134 DOI: 10.1177/0269881115592347] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Riga MS, Teruel-martí V, Sánchez C, Celada P, Artigas F. Subchronic vortioxetine treatment –but not escitalopram– enhances pyramidal neuron activity in the rat prefrontal cortex. Neuropharmacology 2017;113:148-55. [DOI: 10.1016/j.neuropharm.2016.09.024] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
2 Liguori C, Ferini-Strambi L, Izzi F, Mari L, Manfredi N, D'Elia A, Mercuri NB, Placidi F. Preliminary evidence that vortioxetine may improve sleep quality in depressed patients with insomnia: a retrospective questionnaire analysis. Br J Clin Pharmacol 2019;85:240-4. [PMID: 30328132 DOI: 10.1111/bcp.13772] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
3 Franklin M, Hlavacova N, Li Y, Bermudez I, Csanova A, Sanchez C, Jezova D. Contrasting effects of vortioxetine and paroxetine on pineal gland biochemistry in a tryptophan-depletion model of depression in female rats. Prog Neuropsychopharmacol Biol Psychiatry 2017;79:499-502. [PMID: 28802861 DOI: 10.1016/j.pnpbp.2017.08.008] [Reference Citation Analysis]
4 Xue W, Wang P, Li B, Li Y, Xu X, Yang F, Yao X, Chen YZ, Xu F, Zhu F. Identification of the inhibitory mechanism of FDA approved selective serotonin reuptake inhibitors: an insight from molecular dynamics simulation study. Phys Chem Chem Phys 2016;18:3260-71. [DOI: 10.1039/c5cp05771j] [Cited by in Crossref: 43] [Cited by in F6Publishing: 17] [Article Influence: 7.2] [Reference Citation Analysis]
5 Wilson S, Højer AM, Buchberg J, Areberg J, Nutt DJ. Differentiated effects of the multimodal antidepressant vortioxetine on sleep architecture: Part 1, a pharmacokinetic/pharmacodynamic comparison with paroxetine in healthy men. J Psychopharmacol 2015;29:1085-91. [PMID: 26253622 DOI: 10.1177/0269881115599387] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
6 Hlavacova N, Li Y, Pehrson A, Sanchez C, Bermudez I, Csanova A, Jezova D, Franklin M. Effects of vortioxetine on biomarkers associated with glutamatergic activity in an SSRI insensitive model of depression in female rats. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2018;82:332-8. [DOI: 10.1016/j.pnpbp.2017.07.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
7 Riga MS, Sanchez C, Celada P, Artigas F. Sub-chronic vortioxetine (but not escitalopram) normalizes brain rhythm alterations and memory deficits induced by serotonin depletion in rats. Neuropharmacology 2020;178:108238. [DOI: 10.1016/j.neuropharm.2020.108238] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
8 Amat-foraster M, Leiser SC, Herrik KF, Richard N, Agerskov C, Bundgaard C, Bastlund JF, de Jong IE. The 5-HT6 receptor antagonist idalopirdine potentiates the effects of donepezil on gamma oscillations in the frontal cortex of anesthetized and awake rats without affecting sleep-wake architecture. Neuropharmacology 2017;113:45-59. [DOI: 10.1016/j.neuropharm.2016.09.017] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
9 Danielak D. Vortioxetine in management of major depressive disorder - a favorable alternative for elderly patients? Expert Opin Pharmacother 2021;22:1167-77. [PMID: 33650935 DOI: 10.1080/14656566.2021.1880567] [Reference Citation Analysis]
10 De Diego-Adeliño J, Crespo JM, Mora F, Neyra A, Iborra P, Gutiérrez-Rojas L, Salonia SF. Vortioxetine in major depressive disorder: from mechanisms of action to clinical studies. An updated review. Expert Opin Drug Saf 2021;:1-18. [PMID: 34964415 DOI: 10.1080/14740338.2022.2019705] [Reference Citation Analysis]
11 Franklin M, Hlavacova N, Li Y, Bermudez I, Csanova A, Sanchez C, Jezova D. Reprint of: Contrasting effects of vortioxetine and paroxetine on pineal gland biochemistry in a tryptophan-depletion model of depression in female rats. Prog Neuropsychopharmacol Biol Psychiatry 2018;82:339-42. [PMID: 29277417 DOI: 10.1016/j.pnpbp.2017.12.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]